FDA adds border screening for GLP-1 ingredients and warns of fake pharmacy names on compounded vials

Federal regulators have added two layers to their guidance on unapproved GLP-1 drugs: a border screen for the raw ingredients used to make compounded versions, and a warning that some finished vials carry labels naming pharmacies that had no role in producing them ^[1][2].

The screen is a green list import alert, designated 66-80, covering GLP-1 active pharmaceutical ingredients, the bulk drug substances compounders buy to make finished medicine ^[1]. Ingredients from manufacturers that FDA judges to have quality or manufacturing problems can be refused entry. Companies the agency has inspected or otherwise evaluated and found to follow its manufacturing standards are not covered by the alert ^[1]. FDA says the measure leaves legal importation from compliant suppliers intact and places no additional restrictions on lawful compounding ^[1].

Fake pharmacy names on labels

The same update describes fraudulent compounded semaglutide and tirzepatide on the U.S. market whose labels carry false details ^[1]. Two patterns are described: labels naming a compounding pharmacy that does not exist at all, and labels naming a real licensed pharmacy that, according to what FDA has learned, did not produce the medicine ^[1][2].

FDA cites one reported adverse event tied to a product labeled as compounded tirzepatide from a pharmacy that did not compound it. The report described redness, swelling and pain at the injection site, plus a red lump ^[1].

Broader totals are larger. Through May 31, 2026, FDA had logged 990 adverse event reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide ^[1]. The agency cautions that state-licensed pharmacies that are not outsourcing facilities are not required to report adverse events, so the true count is likely higher, and that it often cannot determine whether a drug caused a given event or whether other factors played a role ^[1].

Other safety issues the agency repeats

FDA says it has received multiple reports, some involving hospitalization, that may be tied to dosing mistakes with compounded injectable semaglutide: patients measuring or injecting the wrong amount, or clinicians miscalculating a dose ^[1]. Other reports involve compounded semaglutide or tirzepatide given at levels beyond the approved label's dosing, whether as a bigger single dose, more frequent doses or a faster step-up ^[1].

The page also states that some semaglutide sold by compounders may be salt forms, including semaglutide sodium and semaglutide acetate, which differ from the active ingredient in approved products. FDA says it is not aware of a lawful basis for using them in compounding ^[1]. Retatrutide and cagrilintide cannot legally be used in compounding, the agency adds ^[1].

Two storage and handling points appear as well: multi-dose vials should be discarded 28 days after first use even if medicine remains, and an injectable GLP-1 that arrives warm or with inadequate ice should not be used ^[1].

Why it matters for patients

Compounded drugs do not go through FDA review for safety, effectiveness or quality before they reach the market, so the label is often the only clue a patient has about who made the product ^[1]. The update says that clue can be wrong in either direction: an invented pharmacy name, or a genuine one attached to a product it never made ^[1][2].

The import alert works upstream, at the ingredient level. It does not verify the contents of a vial a patient already has, and FDA states it adds no new limits on legal compounding ^[1].

FDA lists warning signs for telehealth buyers: labels with misspellings or wrong pharmacy addresses, claims that a compounded drug matches an FDA-approved one, steep discounts, medicine arriving in damaged packaging or without instructions for use, and sellers that ship without a licensed prescriber's screening and prescription ^[1]. The agency's stated position is that compounded drugs should be used only when a patient's medical need cannot be met by an approved product, and that patients should get a prescription from their doctor and fill it at a state-licensed pharmacy ^[1].

What happens next

An effective date, a compliance deadline and a list of affected ingredient manufacturers have not been disclosed ^[1]. FDA has not said how many products or labels it has identified as fraudulent, or whether enforcement actions are planned ^[1].